Tech billionaires invest $5B in AI for human life extension
Serge Bulaev
Tech billionaires are pouring more than $5 billion into high-tech companies to try to make people live longer. Using smart computers, these companies search for ways to slow down or even reverse aging, with big names like Jeff Bezos and Sam Altman leading the charge. Some pills and therapies are already being tested on humans for diseases like Alzheimer's. But many people are worried that only the rich might benefit and that important resources could shift away from other health problems. The next two years will show if these new treatments actually work, sparking even bigger questions about who gets to live longer.
Backed by over $5 billion from tech billionaires, the use of AI for human life extension is now a high-stakes race to re-engineer biology. This capital funds private companies using machine learning to analyze vast biological datasets, identify the drivers of aging, and fast-track new therapies into human trials.
Where the money is going
Tech billionaires are financing a new wave of biotechnology firms that use artificial intelligence to accelerate anti-aging research. These companies analyze complex biological data to identify therapies that can slow or reverse aging processes, with leading contenders already advancing their treatments into human clinical trials.
Backed by OpenAI's Sam Altman, Retro Biosciences secured $1 billion in funding. The company leverages an OpenAI partnership that reportedly makes cellular reprogramming 50 times more efficient (Fortune) and has advanced its lead drug, RTR242, into an early-stage Alzheimer's trial.
Altos Labs, backed by Amazon founder Jeff Bezos, holds the industry's largest funding at $3 billion. The company is establishing global institutes to research partial epigenetic reprogramming, a technique that has already extended lifespans in preclinical mouse studies (Business Insider).
Other key players include Life Biosciences, which is preparing its PER therapy for Phase 1 trials by 2026, and Shift Biosciences, which raised $16 million for its generative-AI cell simulator. Meanwhile, Insilico Medicine has already moved an AI-discovered drug for pulmonary fibrosis through a Phase 2a study, demonstrating the speed of data-driven research.
Why tech moguls care
Prominent investors like Sam Altman, Jeff Bezos, and Peter Thiel view aging not as inevitable but as the primary cause of most chronic diseases. This perspective is bolstered by a market projected to grow from $85 billion in 2025 to $120 billion by 2030. Personal motivations also play a role; for example, Sergey Brin has a genetic predisposition to Parkinson's disease, and Thiel has long funded anti-aging research.
Early signs of clinical traction
- Retro Biosciences began dosing volunteers with its autophagy-boosting pill in 2025.
- Altos Labs is actively recruiting for its first human trial focused on epigenetic reprogramming.
- Life Biosciences aims to file for an Investigational New Drug (IND) for its ER-100 candidate within 12 months.
- Insilico Medicine's TNIK inhibitor successfully completed a mid-stage trial for pulmonary fibrosis.
- The XPRIZE Healthspan competition is set to award $10 million to each of ten finalists demonstrating functional health improvements over one year.
Ethical questions gaining volume
The surge in private funding from billionaires has raised significant ethical questions, with policy experts warning of research agendas skewed toward elite priorities. Bioethicists highlight four primary concerns:
- Access and Equity: Will rejuvenation therapies, potentially costing over $100,000, worsen existing health disparities?
- Resource Allocation: Does focusing on life extension divert critical funding from more immediate public health issues like infectious diseases?
- Regulatory Influence: Could powerful private donors disproportionately shape government regulations for future aging treatments?
- Societal Impact: How would widespread life extension affect societal structures, including pension systems and workforce dynamics?
In response, regulatory bodies are taking notice. The U.S. FDA established a task force on longevity trials in late 2024, while the European Medicines Agency is developing new guidance for biomarkers that measure biological, not chronological, age.
What happens next
The years 2025-2026 represent a critical turning point, as companies like Retro and Altos move from speculative research to generating concrete clinical data from human trials. A significant breakthrough - even the durable reversal of a single aging marker - could cause the sector's valuation to soar past its current $5 billion, intensifying the global debate over who has access to a longer life.
Who are the main tech billionaires investing in AI-driven life extension?
Key investors include Sam Altman (Retro Biosciences), who is backing a $1 billion effort to extend healthspan, and Jeff Bezos (Altos Labs), who has committed $3 billion to cellular rejuvenation. Other major funders are Peter Thiel, Brian Armstrong, and Sergey Brin, who have invested hundreds of millions into related anti-aging and health research.
How is AI specifically being used to extend human lifespan?
AI is used to dramatically accelerate research. For example, Retro Biosciences reports that AI makes cellular reprogramming 50 times more efficient, while Insilico Medicine used AI to develop the first AI-discovered drug to clear Phase 2a trials. Other firms like Shift Biosciences and BioAge Labs use AI to analyze data and pinpoint promising rejuvenation targets.
Which companies are closest to human trials?
Several companies are already in or near the clinical stage. Retro Biosciences has started human trials in Australia for its Alzheimer's drug RTR242. Life Biosciences is aiming for clinical development of its ER-100 candidate by early 2026, and Altos Labs is preparing for human studies following successful trials in mice.
What motivates billionaires to fund longevity research?
Investors often frame aging as a treatable disease and the root cause of widespread suffering. Beyond personal health interests, such as Brin's genetic risk for Parkinson's, there is significant market potential. The anti-aging industry is projected to grow from $85 billion in 2025 to $120 billion by 2030.
What are the main ethical concerns surrounding these investments?
Primary ethical concerns focus on equity and access, questioning who can afford potentially expensive treatments. Other major issues include the allocation of resources away from pressing public health crises and the outsized influence of billionaire donors on the direction of scientific research and future government regulation.